Science spotlight: Roche’s anti-TIGIT mAb benefits from Fc-driven effects and more

A Nature paper suggests that Fc domain functionality is an important consideration in anti-TIGIT mAb development, and could be a key driver of efficacy for Roche’s tiragolumab.

Researchers from the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) and collaborators from multiple institutions showed that anti-TIGIT mAb tiragolumab, which has a glycosylated IgG1 Fc region that binds Fcy receptors, remodeled the immunosuppressive tumor microenvironment to increase the efficacy of anti-PD-L1 mAb Tecentriq in non-small cell lung cancer patients...